Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006864 · ClinicalTrials.gov registry record · Phase 4
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
A Phase 4 study of Kidney Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 2
- Study locations
NCT00006864 is a Phase 4 study of Kidney Cancer that has completed, run by Case Comprehensive Cancer Center. The trial reports 2 study locations across 2 states.
The verdict
NCT00006864, a Phase 4 study of Kidney Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
Study Locations (2)
Connecticut
- Northwestern Connecticut Oncology-Hematology Associates - Torrington
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006864
The ClinicalTrials.gov registry entry for NCT00006864 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which aldesleukin is the first listed.
NCT00006864 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Ohio.
Frequently Asked Questions
What is clinical trial NCT00006864 about?
NCT00006864 is a clinical study titled "Interleukin-2 in Treating Patients With Metastatic Kidney Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients who have metastatic kidney cancer.
What is the current status of trial NCT00006864?
This trial is currently completed. It is a Phase 4 study. The study started on 2000-07. Estimated completion is 2007-07.
What conditions does trial NCT00006864 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00006864?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006864?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006864 being conducted?
This trial has 2 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preop Laxatives in Robotic Urologic Surgery
RECRUITING · Phase 4
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RECRUITING
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.